Cost cuts are coming for Allergan, CEO Brent Saunders says

Discussion in 'Allergan' started by anonymous, Nov 3, 2017 at 5:42 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    No I meant we would have been better off years ago under BS instead of DP
     
  2. anonymous

    anonymous Guest


    How so? BS is crap!
     
  3. anonymous

    anonymous Guest

    BS does what is right for shareholders. BS does what is necessary to protect the best brands like Restasis. He built to where it is today. From a leadership standpoint there is no comparison. We might not agree with every decision but we usually see why the decision was made later and we understand. His job is not the easiest one in the world but he is a top performer and would have been a welcomed edition to Allergan when DP lost control.
     
  4. anonymous

    anonymous Guest


    And believe me us shareholders are thrilled to see the stock go from $300 to $172. Being the subject of a congressional inquiry is great also!
     
  5. anonymous

    anonymous Guest

    BS lost a patent he had 7 more years on. He made a stupid decision and guess what? WE will be punished for it while he gets to keep making millions

    If he were a real leader, the cost cutting would come from HIS salary because of the decision HE made. But instead our heads will roll, not his.
     
  6. anonymous

    anonymous Guest

    Where do you come up with this Bullshit?
    And who are you referring to as "we?"

    Do you think Brent magically started the Restasis brand at the completion of the takeover? I might remind you that was June of 2015. He's done nothing but spend the surplus that he inherited with was a great and respected company.

    Kool-aid drinking fool.
     
  7. anonymous

    anonymous Guest

  8. anonymous

    anonymous Guest

  9. anonymous

    anonymous Guest



    BS is arguably the worst CEO in pharma! Wonder what you will think if the board feels pressure from shareholders to remove him from CEO. He's already over spent on M&A that's failed with NASH and we got 3 phase 3's in 2018 that either hit big with the data or this stock tanks to $100. At that point shareholders will be after him!
     
  10. anonymous

    anonymous Guest


    Sure we have a few missteps but let that all fall on the shoulders of BS. His business acumen and leadership qualities combined with the value he has extracted from cyclosporine can not believe overlooked.
     
  11. anonymous

    anonymous Guest

    * can’t fall on his shoulders (sorry)
     
  12. anonymous

    anonymous Guest



    You are clueless!
     
  13. anonymous

    anonymous Guest

    This is where you are mistaken. He hasn't extracted value from Restasis. Everything was already in place regarding Restasis. The product was already almost at a billion dollars in sales before he became CEO. The patent extensions were already in place before he became CEO. The registrations in Europe were already planned before he became CEO. He has simply followed the course that was already in place regarding Restasis.
     
  14. anonymous

    anonymous Guest

    He developed the MD bottle with no preservative to extend our usage for years
     
  15. anonymous

    anonymous Guest

    Nope, the MDPF bottle was developed and the regulatory filing almost ready to be submitted before the takeover.